TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy

Cheryl E. G. Leyns1,a,b,c, Jason D. Ulrich1,a,b,c, Mary B. Finn1,a,b,c, Floy R. Stewart1,a,b,c, Lauren J. Kosca1,a,b,c, Javier Remolina Serrano1,a,b,c, Grace O. Robinson1,a,b,c, Elise Anderson1,a,b,c, Marco Colonna1, and David M. Holtzman1,a,b,c

1Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110; 2Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110; 3Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110; and 4Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110

Edited by Don W. Cleveland, University of California, San Diego, La Jolla, CA, and approved September 15, 2017 (received for review June 7, 2017)

Variants in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) were recently found to increase the risk for developing Alzheimer’s disease (AD). In the brain, TREM2 is predominately expressed on microglia, and its association with AD adds to increasing evidence implicating a role for the innate immune system in AD initiation and progression. Thus far, studies have found TREM2 is protective in the response to amyloid pathology while variants leading to a loss of TREM2 function impair microglial signaling and are deleterious. However, the potential role of TREM2 in the context of tau pathology has not yet been characterized. In this study, we crossed Trem2+/− (T2+/−) and Trem2−/− (T2−/−) mice to the PS19 human tau transgenic line (PS) to investigate whether loss of Trem2 function affected tau pathology, the microglial response to tau pathology, or neurodegeneration. Strikingly, by 9 mo of age, T2−/−PS mice exhibited significantly less brain atrophy as quantified by ventricular enlargement and preserved cortical volume in the entorhinal and piriform regions compared with T2+/−PS mice. However, no TREM2-dependent differences were observed for phosphorylated tau staining or insoluble tau levels. Rather, T2−/−PS mice exhibited significantly reduced microgliosis in the hippocampus and piriform cortex compared with T2+/−PS mice. Gene expression analyses and immunostaining revealed microglial activation was significantly attenuated in T2−/−PS mice, and there were lower levels of inflammatory cytokines and astrogliosis. These unexpected findings suggest that impairing microglial TREM2 signaling reduces neuroinflammation and is protective against neurodegeneration in the setting of pure tauopathy.

A
ldzheimer’s disease (AD) is the most prevalent form of dementia and is thought to be caused by accumulation of two different proteins in the brain. Amyloid-β (Aβ) aggregates form extracellular plaques, while hyperphosphorylated tau (p-tau) is present in intracellular neurofibrillary tangles (1). Microgliosis, or activation of the innate immune cells in the brain, is an additional pathological signature routinely found in regions affected by abundant plaques and tangles (2, 3). Chronic microgliosis has long been hypothesized to influence accumulation of Aβ and tau, contribute to neuronal damage, and ultimately exacerbate neurodegeneration (4, 5). However, studies over the past two decades have reported both beneficial and detrimental effects of microgliosis in AD (4, 5). Thus, the role of microgliosis and inflammation in disease onset and progression remains poorly understood.

The discovery that rare coding variants in the triggering receptor expressed on myeloid cells 2 (TREM2) are associated with a twofold to fourfold increased risk for developing sporadic, late-onset AD further implicates the role of microglia in AD (6, 7). TREM2 is specifically expressed in microglia in the brain and has been shown to impact a multitude of functions including activation, inflammation, phagocytosis, proliferation, and survival (8). Although the exact molecular effects of AD-associated risk variants in TREM2 are still being investigated, the most common position 47 arginine-to-histidine (R47H) variant appears to reduce binding to anionic phospholipids, including binding to apolipoproteins such as ApoE, and reduce lipid-induced TREM2 activity (9–14). The exact physiological ligand(s) of TREM2 are currently unknown, but it is this thought that decreased ligand binding results in a loss of microglial functions, which consequently increases risk for the development of AD (8).

AD pathology is characterized first by the appearance of Aβ plaques followed by the spread of neurofibrillary tau tangles from the transentorhinal region, to the hippocampus, and into the neocortex (15). Several studies have investigated the effects of TREM2 on plaque deposition and associated pathologies (14, 16–20). One consistent observation has been that reduction or loss of TREM2 function reduces the number of plaque-associated microglia. However, the effects of TREM2 deficiency on overall plaque load have been variable (8). Interestingly, two recent reports found that, despite no difference in the number of plaques, alterations in plaque composition and morphology corresponded

Significance

Alzheimer’s disease (AD) is the most common cause of dementia and is a major public health problem for which there is currently no disease-modifying treatment. There is an urgent need for greater understanding of the molecular mechanisms underlying neurodegeneration in patients to create better therapeutic options. Recently, genetic studies uncovered novel AD risk variants in the microglial receptor, triggering receptor expressed on myeloid cells 2 (TREM2). Previous studies suggested that loss of TREM2 function worsens amyloid-β (Aβ) plaque-related toxicity. In contrast, we observe TREM2 deficiency mitigates neuroinflammation and protects against brain atrophy in the context of tau pathology. These findings indicate dual roles for TREM2 and microglia in the context of amyloid versus tau pathology, which are important to consider for potential treatments targeting TREM2.

Author contributions: C.E.G.L., J.D.U., and D.M.H. designed research; C.E.G.L., J.D.U., M.B.F., F.R.S., L.J.K., J.R.S., G.O.R., and E.A. performed research; M.C. contributed new reagents/analytic tools; C.E.G.L. and J.D.U. analyzed data; and C.E.G.L. wrote the paper.

Conflict of interest statement: C.E.G.L. and D.M.H. are listed as inventors on a patent licensed by Washington University to CN2 Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. cofounded and is on the scientific advisory board of CN2 Diagnostics, LLC. CN2 Diagnostics, LLC, has licensed certain anti-tau antibodies to AbbVie for therapeutic development. D.M.H. is on the scientific advisory board of Proclara Biosciences and consults for Genentech, Eli Lilly, AbbVie, GlaxoSmithKline, and Denali. J.D.U., M.B.F., F.R.S., L.J.K., J.R.S., G.O.R., E.A., and M.C. declare no competing financial interests.

This article is a PNAS Direct Submission.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

1C.E.G.L. and J.D.U. contributed equally to this work.

2To whom correspondence should be addressed. Email: holtzman@wustl.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1710311114/-/DCSupplemental.
to increased neuritic dystrophy and p-tau accumulation around plaques in Trem2-deficient mouse models and in human R47H variant carriers (19, 20). Therefore, TREM2 is currently thought to be protective in the response to amyloid pathologies, while variants leading to a loss of TREM2 function impair microglia signaling and are deleterious. However, the potential role of TREM2 in the context of tau pathology has not yet been characterized.

In this study, we aimed to investigate whether TREM2 affected tau pathology, the microglial response to tauopathy, or neurodegeneration. Surprisingly, despite finding no significant changes in tau accumulation, we observed attenuated brain atrophy together with reduced microglial activation in PS19 human tau (htau) transgenic mice lacking TREM2. Collectively, our data demonstrate that TREM2 mitigates the microglial response to tau pathology or damage induced by tau aggregates, which protects against neurodegeneration.

**Results**

**TREM2 Deficiency in PS19 Mice Attenuates Tau-Mediated Neurodegeneration.** To investigate the effects of TREM2 on tauopathy, we crossed Trem2<sup>−/−</sup> (T2<sup>−/−</sup>) and Trem2<sup>+/−</sup> (T2<sup>+/−</sup>) mice (21) to PS19 tau-transgenic mice to generate T2<sup>−/−</sup>PS and T2<sup>+/−</sup>PS mice. PS19 mice express an htau transgene containing a P301S mutation that is causative for a familial form of frontal temporal dementia (FTD). These mice acquire substantial tangle deposition and gliosis by 9 months of age (22). Additionally, PS19 mice develop gross neurodegeneration culminating in severe brain atrophy that can be visibly observed through enlargement of the lateral ventricles and thinning of hippocampal and certain cortical regions (22). In this study, we only examined male mice as there is significantly more tau pathology and neurodegeneration in male versus female PS19 mice (23).

We initially observed a striking and unexpected attenuation of neurodegeneration in T2<sup>−/−</sup>PS compared with T2<sup>+/−</sup>PS mice (Fig. L4). By performing a stereological assessment, we determined that there was significantly less ventricular enlargement in T2<sup>−/−</sup>PS mice compared with T2<sup>+/−</sup>PS littermates (Fig. 1A and B). Notably, there is variability in that mice appear to have substantial ventricular enlargement (ventricles >1 mm<sup>3</sup>) or not, with ~47% of T2<sup>−/−</sup>PS mice showing markedly enlarged ventricles as opposed to ~16% of T2<sup>+/−</sup>PS mice (Fig. 1B). This finding corresponded with significant preservation of the entorhinal and piriform cortex volume in T2<sup>−/−</sup>PS mice (Fig. 1A and C). While no significant changes in hippocampal volume were observed (Fig. 1A and D), levels of the synaptic protein, PSD-95, were significantly lower in T2<sup>−/−</sup>PS mice (Fig. 1E and F), indicating more synaptic degeneration in this region compared with T2<sup>+/−</sup>PS mice. The reduced brain atrophy and preservation of PSD-95 in T2<sup>−/−</sup>PS mice suggests that loss of TREM2 function is neuroprotective in the setting of tauopathy.

**TREM2 Deficiency Does Not Alter Phosphorylated or Insoluble Tau Levels.** To investigate whether the preservation of brain volume in T2<sup>−/−</sup>PS mice was due to a reduction in overall tau deposition, we assessed the accumulation of p-tau and insoluble tau aggregates in T2<sup>−/−</sup>PS and T2<sup>+/−</sup>PS mice. The tau monoclonal antibody, AT8, recognizes a double phosphorylation epitope (pS202, pT205) and has been shown to primarily stain intraneuronal and extraneuronal neurofibrillary tangles associated with Braak stages IV, V, and VI (24). Staining with biotinylated AT8 did not reveal any significant differences in p-tau deposition between 9-mo-old T2<sup>−/−</sup>PS and T2<sup>+/−</sup>PS mice in the piriform cortex (Fig. 2A and B) or hippocampus (Fig. 2C and D). To further examine tau aggregation in these mice, we performed a sequential biochemical extraction of hippocampal brain tissue. Samples were first extracted in a high-salt RAB buffer, the subsequent pellet was resuspended in a detergent radioimmunoprecipitation assay (RIPA) buffer, and the final pellet was solubilized in 70% formic acid (FA). RAB and RIPA fractions contain more soluble tau species while the 70% FA fraction contains insoluble, tau aggregates. The concentration of tau in each fraction was measured using an htau-specific ELISA. We observed no significant differences in tau levels in any fraction between T2<sup>−/−</sup>PS and T2<sup>+/−</sup>PS mice (Fig. 2E). These data indicate that TREM2 deficiency does not result in obvious changes to p-tau accumulation or tau solubility despite the attenuated neurodegenerative phenotype.

**Microgliosis Is Impaired in T2<sup>−/−</sup>PS Mice in the Presence of Tauopathy.** Given that the lack of Trem2 expression did not significantly affect p-tau or insoluble tau levels in PS19 mice, we hypothesized that attenuation of the neurodegenerative phenotype in these mice may be attributed to the microglial response to tau accumulation. Reactive microglia have been described in brain regions affected by a high density of tau tangles both in AD as well as in other primary tauopathies such as FTD (2, 5, 25). Staining for the microglial marker, Iba1, revealed significantly reduced microgliosis in the piriform cortex (Fig. 3A and B) and hippocampus (Fig. 3C and D) of T2<sup>−/−</sup>PS mice compared with T2<sup>+/−</sup>PS mice. To further assess these findings, we quantified the total number of immunofluorescence-labeled Iba1-positive microglial cell bodies by confocal microscopy and found significantly fewer microglia in the piriform cortex of T2<sup>−/−</sup>PS mice (Fig. 3E). Additionally, we observed that microglia in T2<sup>−/−</sup>PS mice were amoeboid, consistent with increased neuritic dystrophy and p-tau accumulation around plaques in Trem2-deficient mouse models and in human R47H variant carriers (19, 20).

Fig. 1. **TREM2 deficiency attenuates neurodegeneration in PS19 mice.** (A) Representative images of Nissl staining from T2<sup>−/−</sup>PS and T2<sup>+/−</sup>PS mice. (Scale bars, 2.5 mm.) Quantification of the average volume of the (B) ventricles (P = 0.0034; T2<sup>−/−</sup>PS, n = 15; T2<sup>+/−</sup>PS, n = 19), (C) entorhinal and piriform cortex (P = 0.0232; T2<sup>−/−</sup>PS, n = 14; T2<sup>+/−</sup>PS, n = 17), and (D) hippocampus (P = 0.4589; T2<sup>−/−</sup>PS, n = 15; T2<sup>+/−</sup>PS, n = 20). (E) Immunoblot analysis from hippocampal RIPA lysates of PSD-95 in T2<sup>−/−</sup>PS and T2<sup>+/−</sup>PS mice. ERK served as a loading control. (F) Quantification of the relative protein levels for PSD-95 to the internal control, ERK1. Blots shown in E are cropped. Full-length blots are presented in Fig. S1. A Mann-Whitney test was used to determine statistical significance for ventricular volume due to the nonparametric data set. For all other graphs, significance was determined by an unpaired, two-tailed Student's t test. Significance was defined as *P < 0.05 and **P < 0.01.
was performed on cortical tissue from T2+/+PS and T2−/−PS mice to assess the expression of several genes that have been reported as homeostatic (Tmem119 and P2ry12) versus activated (Csf7, Spp1, and Apoe) microglia markers (28-31) (Fig. 4A). Only Apoe and Csf7 transcripts were significantly altered and were lower in T2−/−PS mice, indicating less microglial activation. While Csf7 is a microglia-specific gene (32), Apoe is expressed by both astrocytes and microglia in the brain (33). Increased expression of Apoe in microglia has been recently reported in several neurodegenerative disease models as an indicator of microglial activation in response to amassing pathologies and subsequent cell damage (28-31). Therefore, we investigated whether accrual of tau pathology in the piriform cortex altered accumulation of ApoE specifically in microglia. Communostaining revealed ApoE-positive puncta colocalized within Iba1-positive microglial cell bodies (Fig. 4B). Furthermore, the percentage of microglia displaying this phenotype was significantly lower in T2−/−PS mice (Fig. 4C). These data indicate an overall reduction in microglial activation in the absence of TREM2.

We also assessed several inflammatory markers previously implicated in AD (5). Consistent with the reduction in reactive microglia in T2−/−PS mice, we observed a significant decrease in the expression of both IL-1 isoforms, IL-1β and IL-1α (Fig. 4D). IL-1 signaling has been shown to induce expression of other proinflammatory mediators such as TNF-α and IL-6 (5). Accordingly, TNF-α was significantly down-regulated in T2−/−PS mice; however, IL-6 transcript levels were unaltered (Fig. 4D). In addition to cytokines, complement proteins are reported to be increased in brain regions with AD pathology (5). We found the early subcomponent of the complement cascade, C1q, was significantly down-regulated with a more activated phenotype, whereas microglia in T2−/−PS mice appeared ramified (Fig. 3F). Coating with the proliferative cell marker, Ki67 (19), did not reveal differences between T2+/+PS and T2−/−PS mice (Fig. S2). There were very few proliferative microglia in either group (on average, approximately two microglia from two sections per mouse for both genotypes). Therefore, microglial proliferation does not appear to account for the decrease in the total number of microglia observed in T2−/−PS mice.

The amount of reactive gliosis in human AD patient brains has been reported to more closely correlate with the degree of neurofibrillary tangle pathology as opposed to amyloid plaque burden (26, 27). Indeed, we observed that microgliosis, as measured by Iba1 staining in T2−/−PS mice, significantly correlated with AT8 p-tau staining (Fig. S3A) and the amount of FA-soluble htau (Fig. S3B) in the hippocampus. Interestingly, these correlations were blunted in the absence of TREM2 (Fig. S3A and B). Likewise, the amount of brain atrophy, indicated by increased ventricular volume, significantly correlated with the degree of p-tau staining (Fig. S3C) and amount of FA-soluble htau (Fig. S3D) in T2−/−PS mice. However, these correlations were ablated in T2−/−PS mice (Fig. S3 C and D). Since the p-tau and insoluble tau burden were not significantly different in T2−/−PS and T2+/+PS mice, this suggests that TREM2 deficiency impairs the microglial response to tau accumulation, which protects against brain atrophy.

Nine-Month-Old T2−/−PS Mice Have Decreased Microglial Activation and Expression of Inflammatory Genes. We further wanted to examine whether the loss of TREM2 influenced microglial homeostasis and expression of proinflammatory genes in T2−/−PS mice despite equivalent levels of tauopathy. Quantitative RT-PCR (qRT-PCR)
Astrogliosis Is Reduced in T2−/−PS Mice. Regions burdened by pathology in AD and other neurodegenerative conditions are also characterized by the presence of reactive astrocytes. Recent studies have further demonstrated that microglia can influence astrocyte reactivity in several disease models (34, 35). In our qRT-PCR analyses for inflammatory mediators, we found that the reactive astrocytic marker, glial fibrillary acidic protein (GFAP), was significantly reduced in the cortex of T2−/−PS mice (Fig. 5A). Immunostaining for GFAP confirmed significantly less astrogliosis in both the piriform cortex (Fig. 5B and D) and hippocampus (Fig. 5C and E) of T2−/−PS compared with T2+/+PS mice. The degree of GFAP staining in the hippocampus strongly correlated with the amount of p-tau pathology in both groups (Fig. S4A). Interestingly, however, the correlation between GFAP astrocyte and Iba1 microglia staining was diminished in T2−/−PS compared with T2+/+PS mice (Fig. S4B). This supports the notion that microglia influence reactive astrocytes in tauopathy and that this occurs in a TREM2-dependent manner.

Discussion

Our study provides insights into how loss of TREM2 function impacts tau-associated pathologies and the neurodegeneration that ensues in the brain. Surprisingly, it indicates that TREM2 deficiency in the setting of pure tauopathy limits gliosis and neuroinflammation as well as protects against brain atrophy. T2−/−PS mice had significantly attenuated ventricular enlargement and thinning of the entorhinal and piriform cortex layers compared with T2+/+PS mice despite no significant differences in p-tau and insoluble tau accumulation. Further analysis revealed decreased microgliosis and astrogliosis in regions affected by tauopathy in T2−/−PS mice, which corresponded with reduced expression of several proinflammatory genes. These observations suggest that TREM2 facilitates a microglial response to tau pathology and or tau-mediated damage in the brain. Furthermore, our results support that microglia can contribute to the neurodegenerative process in tauopathy without altering tau aggregation.

The absence of TREM2 is associated with decreased microgliosis in a variety of disease models, but the ultimate effects on the different pathologies and neuronal integrity differ. It has previously been shown that TREM2 mediates a microglial response to amyloidosis although not necessarily impacting total plaque load (20, 21). Reminiscent of these observations, we did not detect any obvious effects on tau deposition in T2−/−PS mice but did find decreased microgliosis in areas with abundant tauopathy. Altogether, these data suggest that lack of TREM2 function impacts microglial response to protein aggregation in AD but does not necessarily aggravate it. However, the consequences of TREM2-mediated microgliosis in the context of plaque and tangle pathologies diverge. Previous work illustrates that TREM2 helps sustain

in T2−/−PS mice (Fig. 4D). Thus, there is a decrease in neuroinflammation in T2−/−PS mice despite tangle deposition and tau-induced damage.

![Fig. 4. Decreased microglial activation and inflammatory gene expression in T2−/−PS mice. (A) Expression of microglial homeostatic (Tmem119; P = 0.1755; and P2ry12; P = 0.6323) and activated markers in the cortex of T2−/−PS and T2−/−PS mice (Cst7; P = 0.0274; Sp1; P = 0.2256; ApoE; P = 0.0088). (B) Representative images of ApoE-positive puncta in Iba1-positive cell bodies from immunofluorescence staining in the piriform cortex of T2−/−PS and T2−/−PS mice. Images represent maximum-intensity projections of z stacks. (Scale bars, 50 μm.) (C) Quantification of the percentage of Iba1-positive microglial cell bodies with ApoE accumulation in the piriform cortex (P = 0.0003; T2−/−PS, n = 12; T2−/−PS, n = 20). (D) Expression of inflammatory genes in the cortex of T2−/−PS and T2−/−PS mice (IL-1α; P = 0.0021; IL-1β; P = 0.0099; TNF-α; P = 0.0133; and C1q, P = 0.0316; IL-6; P = 0.5512). n = 9–10 for all qRT-PCR analyses. All graphs represent the mean ± SEM. Significance was determined using an unpaired, two-tailed Student’s t test with "ns" denoting not significant, *P < 0.05, **P < 0.01, and ***P < 0.001.

![Fig. 5. Reduced astrogliosis in T2−/−PS mice. (A) Expression of cortical GFAP (P = 0.0019). Quantification of the percent area covered by GFAP staining in the (B) piriform cortex (P = 0.0282; T2−/−PS, n = 14; T2−/−PS, n = 20) and (C) hippocampus (P = 0.0067; T2−/−PS, n = 14; T2−/−PS, n = 19). Representative images of GFAP immunohistochemistry in the (D) piriform cortex and (E) hippocampus of T2−/−PS and T2−/−PS mice. (Scale bars, 1 mm.) Data are mean ± SEM. Significance was determined using an unpaired, two-tailed Student’s t test with *P < 0.05 and **P < 0.01.](Image 0x1 to 19x816)
a microglial response around plaques that may function to contain toxic Aβ species and protect surrounding neurites (19, 20). Thus, TREM2 signaling may be beneficial in responding to amyloid pathology, while variants leading to a loss of TREM2 function are detrimental. In contrast, our study revealed lack of TREM2 during tauopathy was neuroprotective, reducing gliosis and neuroinflammation, which corresponded with preservation of brain volume. Furthermore, no effects on p-tau pathology were seen in this model, as opposed to observations of increased neuritic dystrophy and p-tau accumulation surrounding amyloid plaques in TREM2-deficient mice (19, 20). We hypothesize that the increase in p-tau detected around plaques in Trem2−/− mice results from either increased damage from amyloid to surrounding neurites or decreased phagocytic clearance of neurites due to less plaque-associated microglia, whereas the p-tau detected in the PS19 mice is attributable to neuronal tau aggregation. Another report also observed beneficial effects of TREM2 deficiency on neuroinflammation and degeneration. Trem2−/− mice had reduced levels of inflammatory transcripts, less hippocampal atrophy, and rescue of behavioral deficits 120 d after traumatic brain injury (36). Overall, these studies indicate TREM2 signaling is important for facilitating the microglial response to damage in the brain and echo the juxtaposing roles that have been described for microglia in neurodegenerative diseases.

Several mechanisms have been proposed to explain how loss of TREM2 function impacts microglial fitness and contributes to various disease phenotypes. For instance, decreased neuroinflammatory markers in Trem2-deficient stroke, traumatic brain injury, and neuropathic pain models may result from impaired chemotaxis following neuronal injury (30) and decreased microglial activation (36–38). Similarly, we found decreases in the percentage of reactive microglia in regions affected by tauopathy in aged T2−/−PS were associated with reduction in inflammatory transcripts, specifically IL-1β, IL-1α, TNF-α, and C1q, suggesting loss of TREM2 function impacts microglia activation, hindering inflammatory responses. However, these observations cannot be definitively attributed to deficits in microglial activation since microgliosis and astrogliosis were reduced as well, making it unclear whether lower cytokines levels are merely a result of overall decreased gliosis. Administration of an agonistic TREM2 antibody significantly increased TNF-α and IL-1β levels in Trem2−/− mice, indicating a compensatory role for TREM2 signaling (38). However, Trem2−/− has classically been described as modestly anti-inflammatory and loss of function has also been shown to reduce the same inflammatory markers, such as IL-1β and TNF-α, in other studies (21, 39). Therefore, it remains unclear whether and how TREM2 contributes to microglial activation and regulation of neuroinflammation.

TREM2-deficient microglia have also been shown to have impaired proliferative ability and decreased viability. Trem2−/− plaque-associated microglia have increased TUNEL staining indicative of cellular apoptosis (14) and decreased staining of the proliferation marker Ki-67 (19). A recent report further detailed that deficits in cellular metabolism lead to accumulation of autophagic bodies in Trem2−/− microglia and are responsible for decreasing microglial health (40). We did not observe significant differences in microglial proliferation in PS19 mice regardless of Trem2 genotype. Given the reduction in the number of total microglia in T2−/−PS mice is not attributable to cellular proliferation, TREM2-deficient microglia may be undergoing similar metabolic stress which impacts their fitness and capacity to respond to accumulating damage incited by tauopathy, possibly leading to inadvertent cell death. This would also account for the total decrease in microgliosis that was observed. Recent studies provided further evidence that TREM2 promotes microglial survival via the Wnt/β-catenin signaling pathway (41, 42). These results suggest that reduced TREM2 signaling leaves microglia vulnerable to succumbing to pathological insults and injury.

It should be noted that microgliosis deficits do not always equate with increased neuronal injury. Chronic microglial activation has been hypothesized to lead to excessive neuroinflammation that may exacerbate AD pathologies and neurodegeneration (43). Analysis of human AD brain tissue has revealed up-regulation of several inflammatory cytokines in areas of dense tangle pathology and gliosis in AD and other tauopathies (44, 45). Microgliosis induced by protein aggregation may enhance local neuroinflammation and neuronal damage to accelerate disease progression. In this study, we observed that decreased microgliosis, caused by TREM2 deficiency, was associated with less brain atrophy in the context of tau pathology. Since loss-of-function variants in TREM2 are associated with increased risk of AD, we were surprised by this striking protective effect. The attenuation of neurodegeneration and microgliosis observed in TREM2-deficient mice coincides with other recent data from our laboratory in which we found that there was strikingly reduced inflammation and neurodegeneration in PS19 mice lacking ApoE (35). Taken together, these studies suggest that microglial inflammation promotes tau-dependent degeneration. One caveat is that the PS19 mouse is a model of pure tauopathy that expresses a variant of tau that causes FTD and, unlike in AD, does not first develop amyloid plaques. Many groups have reported that loss of TREM2 function exacerbates amyloid-dependent toxicity in mouse models, including accumulation of p-tau and neuritic dystrophy around plaques. Taken together, it is possible that TREM2 function is critical for mitigating amyloid-dependent toxicity early in AD, but subsequently, TREM2-deficient microgliosis becomes detrimental following the onset of tau pathology to promote neurodegeneration. In other words, there may be stage and pathology-specific effects of TREM2 in AD. Moving forward, it is critical that we gain a better understanding of the mechanisms underlying the potential protective and deleterious effects of TREM2 signaling in the setting of AD pathologies. This may be facilitated by mechanistic in vitro studies, further analysis of mouse models, and examining soluble TREM2 fragments detectable in human cerebral spinal fluid throughout the course of AD (46, 47). Elucidating the functions of TREM2 during the progression of AD may lead to increased understanding of the role of innate immunity in AD and aid in developing novel disease-altering treatment strategies.

**Methods**

**Animals.** PS19 Itau transgenic mice (purchased from The Jackson Laboratory, https://www.jax.org/strain/008169) expressing the T34 isoform of human P301S mutation were crossed with Trem2−/− or Trem2+/+ mice to generate Trem2−/− × PS19 (T2−/−PS) and Trem2+/+ × PS19 (T2+/+PS) mice. Only male T2−/−PS and T2+/+PS mice were used for analysis in this study. All mice were on a C57BL/6 background. Animal procedures were performed in accordance with protocols approved by the Animal Studies Committee at Washington University School of Medicine.

**Brain Extraction and Preparation of Tissue Homogenates.** Mice were anesthetized with i.p. pentobarbital (200 mg/kg), followed by perfusion with 3 mL heparin in cold Dulbecco’s PBS. The brains were carefully extracted and cut into two hemispheres. The left hemisphere was collected for immunostaining and fixed in 4% paraformaldehyde overnight before being transferred to 30% sucrose and stored at 4 °C until they were sectioned. Brains were cut coronally into 50-μm sections on a freezing sliding microtome (SM1200R; Leica) and stored in cryoprotectant solution (0.2 M PBS, 15% sucrose, 33% ethylene glycol) at −20 °C until use. The right hemisphere was dissected to isolate the hippocampus for biochemical analysis, and the tissue was kept at −80 °C until analyzed. Biochemical extractions on brain tissue were performed as previously described (48) to assess tau solubility.

**Volumetric Analysis of Brain Sections.** Seven coronal brain sections (300 μm between sections) beginning rostrally at the ventricles to the caudal end of the hippocampus were mounted on slides and allowed to dry overnight. These sections correspond to bregma coordinates −1.23 to −2.69 in the mouse brain atlas (49). The following day, sections were stained in cresyl violet for 6 min and dehydrated in increasing ethanol concentrations followed by xylene and
1. Holtzman DM, Morris JC, Goate AM (2011) Alzheimer’s disease: The challenge of the second century. Sci Transl Med 3:7tr1.

2. Randles K, O’Grady-McKee H, Zhu S, Selkoe D (1989) Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 24:173–182.

3. Sheffield LG, Marquis JG, Berman NE (2000) Regional distribution of cortical microglia parallels that of neurofibrillary tangles in Alzheimer’s disease. Neurosci Lett 285:165–168.

4. Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease—a double-edged sword. Neuron 35:419–432.

5. Leyns CEG, Holtzman DM (2017) Glial contributions to neurodegeneration in tauopathies. Mol Neurodegener 12:50.

6. Guerreiro R, et al.; Alzheimer Genetic Analysis Group (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med 368:117–127.

7. Jonsson T, et al. (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 368:107–116.

8. Urlich JD, Ulland TK, Colonna M, Holtzman DM (2017) Elucidating the role of TREM2 in Alzheimer’s disease. Neuron 94:237–248.

9. Atagi Y, et al. (2015) Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem 290:26043–26050.

10. Bailey CC, DeVaux LB, Razan M (2015) The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J Biol Chem 290:26039–26042.

11. Kobel DL, et al. (2016) Neurodegenerative disease mutations in TREM2 facilitate a functional surface and distinct loss-of-function mechanisms. Elife 5:e20391.

12. Yeh FL, Wang Y, Tom I, Gonzales LC, Sheng M (2016) TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron 91:328–340.

13. Song W, et al. (2017) Alzheimer’s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimers Dement 13:381–387.

14. Wang Y, et al. (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell 160:1061–1071.

15. Musiek ES, Holtzman DM (2015) Three dimensions of the amyloid hypothesis: Time, space and “wiringmen.” Nat Neurosci 18:800–806.

16. Urlich JD, et al. (2014) Altered microglial response to Aβ plaques in APPS1-21 mice heterozygous for TREM2. Mol Neurodegener 9:20.

17. Jay TR, et al. (2015) TREM2 deficiency eliminates TREM2- inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J Exp Med 212:287–295.

18. Jay TR, et al. (2017) Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer’s disease. J Neurosci 37:637–647.

19. Wang Y, et al. (2016) TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213:667–675.

20. Yuan P, et al. (2016) TREM2 haploinsufficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neurofibrillary disease 92:252–264.

21. Turnbull R, et al. (2006) Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 177:3520–3524.

22. Yoshiiya Y, et al. (2007) Synapse loss and microglial activation precede tangles in P301S tauopathy mouse model. Neurosci Lett 533:337–351.

23. Yamamuro K, et al. (2013) Anti-α-tau antibodies that block microtubule aggregation in vitro markedly decrease pathology and improve cognition in vivo. Neurobiol Dis 50:402–414.

24. Augustinack JC, Schneider A, Mandellkov E-M, Hyman BT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol 103:26–35.

25. Bellucci A, Buigini O, Ghetti B, Spillantini MG (2011) Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation. Neurodegener Dis 8:221–229.

26. Ingelsson M, et al. (2004) Early abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62:925–931.

27. Serrano-Pozo A, et al. (2011) Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am J Pathol 179:1373–1384.

28. Keren-Shaul H, et al. (2017) A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169:1276–1290.e17.

29. Butovsky O, et al. (2015) Targeting miR-155 restores normal microglia and attenuates disease in SOD1 mice. Ann Neurol 77:75–99.

30. Mazzarelli F, et al. (2017) TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep 18:1196–1198.

31. Kramersen S, et al. (2017) The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47:566–581.e9.

32. Sinivasan K, et al. (2016) Untangling the brain’s neuroinflammatory and neurodegenerative transcriptional responses. Nat Commun 7:11295.

33. Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2: a006312.

34. Liddelow SA, et al. (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481–487.

35. Shi Y, et al. (2017) APOE markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549:523–527.

36. Saber M, Kokko-Cochran O, Puntambekar S, Lathia JD, Lamb BT (2017) Triggering receptor expressed on myeloid cells 2 deficiency alters acute macrophage distribution and improves recovery after traumatic brain injury. J Neurotrauma 34:423–435.

37. Sieber MW, et al. (2013) Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice following stroke. PloS One 8:e68298.

38. Kobayashi M, Kornishi H, Sayo A, Takai T, Kiyama H (2016) TREM2/DAP12 signal elicits proinflammatory response in microglia and exacerbates neuropathic pain. J Neurosci 36:11138–11150.

39. Colonna M (2003) TREMs in the immune system and beyond. Nat Rev Immunol 3:445–453.

40. Ulland TK, et al. (2017) TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell 170:649–663.e13.

41. Zheng H, et al. (2017) TREM2 promotes microglial survival by activating Wnt/β-catenin pathway. J Neurosci 37:1772–1784.

42. Otero K, et al. (2009) Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat Immunol 10:734–743.

43. Ransohoff RM (2016) How neuroinflammation contributes to neurodegeneration. Science 353:777–783.

44. Lull ME, Block ML (2010) Microglial activation and chronic neurodegeneration. Neurotherapeutics 7:354–365.

45. Wang W-Y, Tan M-S, Yu J-T, Tan L (2015) Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann Transl Med 3:9.

46. Suárez-Cabaret M, et al.; Dominantly Inherited Alzheimer Network (2016) Early changes in CSF TREM2 in dominantly inherited Alzheimer’s disease occur after amyloid deposition and neuronal injury. Sci Transl Med 8:369ra178.

47. Zhong L, et al. (2017) Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med 214:597–607.

48. Ising C, et al. (2017) AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. J Exp Med 214:1227–1238, and erratum (2017) 214:2163.

49. Paxinos G, Franklin K (2008) The Mouse Brain in Stereotaxic Coordinates (Academic, New York).

Leyns et al.